Terms: = Prostate cancer AND TERT, EST2, Q8NG46, Q8N6C3, Q2XS35, O14783, O14746, 7015, hEST2, TCS1, TRT, TP2 AND Treatment
118 results:
1. Myeloid-derived suppressor cells attenuate the antitumor efficacy of radiopharmaceutical therapy using
Muralidhar A; Hernandez R; Morris ZS; Comas Rojas H; Bio Idrissou M; Weichert JP; McNeel DG
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38663936
[TBL] [Abstract] [Full Text] [Related]
2. Triggers for transition from active surveillance to radical treatment of prostate cancer 2008-2020 - a case-control study.
Ahlberg M; Garmo H; Stattin P; Gedeborg R; Edlund C; Holmberg L; Bill-Axelson A
Scand J Urol; 2024 Mar; 59():63-69. PubMed ID: 38482602
[TBL] [Abstract] [Full Text] [Related]
3. Carboxylesterase-overexpressing htert-immortalized human adipose stem cells in prostate tumor growth inhibition by irinotecan.
Kim JH; Oh E; Song ES; Yun CW; Lee SH; Song YS
J Cancer Res Ther; 2023 Oct; 19(7):1731-1742. PubMed ID: 38376272
[TBL] [Abstract] [Full Text] [Related]
4. Early change in apparent diffusion coefficient as a predictor of response to neoadjuvant androgen deprivation and external beam radiation therapy for intermediate- to high-risk prostate cancer.
Franco FB; Leeman JE; Fedorov A; Vangel M; Fennessy FM
Clin Radiol; 2024 Apr; 79(4):e607-e615. PubMed ID: 38302377
[TBL] [Abstract] [Full Text] [Related]
5. Testosterone replacement in men with sexual dysfunction.
Lee H; Hwang EC; Oh CK; Lee S; Yu HS; Lim JS; Kim HW; Walsh T; Kim MH; Jung JH; Dahm P
Cochrane Database Syst Rev; 2024 Jan; 1(1):CD013071. PubMed ID: 38224135
[TBL] [Abstract] [Full Text] [Related]
6. prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism: A Randomized Clinical Trial.
Bhasin S; Travison TG; Pencina KM; O'Leary M; Cunningham GR; Lincoff AM; Nissen SE; Lucia MS; Preston MA; Khera M; Khan N; Snabes MC; Li X; Tangen CM; Buhr KA; Thompson IM
JAMA Netw Open; 2023 Dec; 6(12):e2348692. PubMed ID: 38150256
[TBL] [Abstract] [Full Text] [Related]
7. SENTRI: Single-Particle Energy Transducer for Radionuclide Injections for Personalized Targeted Radionuclide cancer Therapy.
Lee K; Lall R; Chopra S; Evans MJ; Maharbiz MM; Seo Y; Anwar M
Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1575-1584. PubMed ID: 38122990
[TBL] [Abstract] [Full Text] [Related]
8. EMAS position statement: Testosterone replacement therapy in older men.
Kanakis GA; Pofi R; Goulis DG; Isidori AM; Armeni E; Erel CT; Fistonić I; Hillard T; Hirschberg AL; Meczekalski B; Mendoza N; Mueck AO; Simoncini T; Stute P; van Dijken D; Rees M; Lambrinoudaki I
Maturitas; 2023 Dec; 178():107854. PubMed ID: 37845136
[TBL] [Abstract] [Full Text] [Related]
9. Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic castration-resistant prostate cancer receiving prostate-specific membrane antigen targeted radionuclide therapy.
Stangl-Kremser J; Sun M; Ho B; Thomas J; Nauseef JT; Osborne JR; Molina A; Sternberg CN; Nanus DM; Bander NH; Tagawa S
Prostate; 2023 Oct; 83(14):1351-1357. PubMed ID: 37424145
[TBL] [Abstract] [Full Text] [Related]
10. Does testosterone replacement therapy increase the risk of conversion to treatment in patients with prostate cancer on active surveillance?
Daza J; Ahmad A; Shabir U; Jing Z; Shiekh M; Kauffman E; Guru KA; Hussein AA
Urol Oncol; 2023 Oct; 41(10):429.e1-429.e7. PubMed ID: 37423815
[TBL] [Abstract] [Full Text] [Related]
11. Dimethylarginine Dimethylaminohydrolase - 1 expression is increased under tBHP-induced oxidative stress regulates nitric oxide production in PCa cells attenuates mitochondrial ROS-mediated apoptosis.
Asha Parveen SM; Kami Reddy KR; Ummanni R
Nitric Oxide; 2023 Sep; 138-139():70-84. PubMed ID: 37423418
[TBL] [Abstract] [Full Text] [Related]
12. Response to RL-225Ac in prostate cancer: Effect of prior treatment with RL-177Lu: A systematic review of the literature.
Stangl-Kremser J; Ricaurte-Fajardo A; Subramanian K; Osborne JR; Sun M; Tagawa ST; Bander NH
Prostate; 2023 Jul; 83(10):901-911. PubMed ID: 36960580
[TBL] [Abstract] [Full Text] [Related]
13. Clinical sequencing identifies potential actionable alterations in a high rate of urachal and primary bladder adenocarcinomas.
Varadi M; Nagy N; Reis H; Hadaschik B; Niedworok C; Modos O; Szendroi A; Ablat J; Black PC; Keresztes D; Csizmarik A; Olah C; Gaisa NT; Kiss A; Timar J; Toth E; Csernak E; Gerstner A; Mittal V; Karkampouna S; Kruithof de Julio M; Gyorffy B; Bedics G; Rink M; Fisch M; Nyirady P; Szarvas T
Cancer Med; 2023 Apr; 12(7):9041-9054. PubMed ID: 36670542
[TBL] [Abstract] [Full Text] [Related]
14. Antitumor efficacy of
Potluri HK; Ferreira CA; Grudzinski J; Massey C; Aluicio-Sarduy E; Engle JW; Kwon O; Marsh IR; Bednarz BP; Hernandez R; Weichert JP; McNeel DG
J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 36002185
[TBL] [Abstract] [Full Text] [Related]
15. The role of testosterone in men's health: is it time for a new approach?
Diokno AC
Int Urol Nephrol; 2022 Nov; 54(11):2767-2774. PubMed ID: 35909146
[TBL] [Abstract] [Full Text] [Related]
16. Preclinical Assessment of the Combination of PSMA-Targeting Radionuclide Therapy with PARP Inhibitors for prostate cancer treatment.
Ruigrok EAM; Verkaik NS; de Blois E; de Ridder C; Stuurman D; Roobol SJ; Van Gent DC; de Jong M; Van Weerden WM; Nonnekens J
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887398
[TBL] [Abstract] [Full Text] [Related]
17. Fast beta-emitter Monte Carlo simulations and full patient dose calculations of targeted radionuclide therapy: introducing egs_mird.
Martinov MP; Opara C; Thomson RM; Lee TY
Med Phys; 2022 Sep; 49(9):6137-6149. PubMed ID: 35650012
[TBL] [Abstract] [Full Text] [Related]
18. Safety of androgen therapy in men with prostate cancer.
Rajan P; Tharakan T; Chen R
Best Pract Res Clin Endocrinol Metab; 2022 Sep; 36(5):101628. PubMed ID: 35248487
[TBL] [Abstract] [Full Text] [Related]
19. The Andrographolide Analogue 3A.1 Synergizes with Taxane Derivatives in Aggressive Metastatic prostate cancers by Upregulation of Heat Shock Proteins and Downregulation of MAT2A-Mediated Cell Migration and Invasion.
Mitra Ghosh T; Kansom T; Mazumder S; Davis J; Alnaim AS; Jasper SL; Zhang C; Bird A; Opanasopit P; Mitra AK; Arnold RD
J Pharmacol Exp Ther; 2022 Mar; 380(3):180-201. PubMed ID: 34949650
[TBL] [Abstract] [Full Text] [Related]
20. Somatic Features of Response and Relapse in Non-muscle-invasive Bladder cancer Treated with Bacillus Calmette-Guérin Immunotherapy.
Bacon JVW; Müller DC; Ritch E; Annala M; Dugas SG; Herberts C; Vandekerkhove G; Seifert H; Zellweger T; Black PC; Bubendorf L; Wyatt AW; Rentsch CA
Eur Urol Oncol; 2022 Dec; 5(6):677-686. PubMed ID: 34895867
[TBL] [Abstract] [Full Text] [Related]
[Next]